Top Page
Shanghai Henlius Biotech, Inc. Class H
(2696)
Shanghai Henlius Biotech, Inc. Class H (2696) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Henlius Biotech, Inc. Class H Business Overview & Revenue Model
Shanghai Henlius Biotech, Inc. Class H Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 5.72B | 5.39B | 3.21B | 1.68B | 587.59M | Gross Profit |
| 4.18B | 3.92B | 2.37B | 1.16B | 405.47M | EBIT |
| 939.13M | 631.70M | -586.58M | -871.75M | -949.85M | EBITDA |
| 1.15B | 911.33M | -310.61M | -671.74M | -814.06M | Net Income Common Stockholders |
| 820.47M | 546.02M | -695.26M | -984.05M | -1.04B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 772.96M | 1.01B | 833.66M | 154.98M | 1.11B | Total Assets |
| 10.60B | 9.90B | 8.92B | 7.17B | 6.44B | Total Debt |
| 3.65B | 4.09B | 3.68B | 2.62B | 1.83B | Net Debt |
| 2.88B | 3.11B | 3.00B | 2.47B | 719.31M | Total Liabilities |
| 7.58B | 7.71B | 7.29B | 4.88B | 3.24B | Stockholders Equity |
| 3.01B | 2.19B | 1.64B | 2.30B | 3.20B |
| Cash Flow | Free Cash Flow | |||
| 404.68M | 36.48M | -383.67M | -1.04B | -2.12B | Operating Cash Flow |
| 1.24B | 1.05B | 981.62M | 90.39M | -609.58M | Investing Cash Flow |
| -909.97M | -1.00B | -1.36B | -1.68B | -1.51B | Financing Cash Flow |
| -643.37M | 144.43M | 858.02M | 648.30M | 995.79M |
Shanghai Henlius Biotech, Inc. Class H Technical Analysis
Shanghai Henlius Biotech, Inc. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $48.45B | 21.60 | 14.19% | 1.44% | 14.36% | 33.22% | |
76 Outperform | HK$101.88B | 22.16 | 13.20% | 4.42% | -9.60% | -27.18% | |
74 Outperform | $100.29B | 27.80 | 8.17% | ― | 7.52% | -1.92% | |
72 Outperform | HK$24.78B | 27.86 | 31.65% | ― | 4.23% | 47.71% | |
66 Neutral | $81.38B | 42.88 | 6.14% | 1.32% | 7.63% | -24.23% | |
59 Neutral | HK$3.76B | 21.09 | 4.47% | ― | -9.75% | ― | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% |
Shanghai Henlius Biotech, Inc. Class H Corporate Events
Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius Europe GmbH, received orphan-drug designation from the European Commission for HLX22, a recombinant humanized anti-HER2 monoclonal antibody injection, for the treatment of gastric cancer. This designation, which follows a positive opinion from the European Medicines Agency, highlights the company’s progress in developing HLX22, which is undergoing various clinical trials for different cancer indications. The global market for HER2-targeting monoclonal antibody products was valued at approximately $9.029 billion in 2024, indicating significant market potential for HLX22.
Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a Phase 1/3 clinical study of its Ipilimumab biosimilar, HLX13, for the treatment of unresectable advanced hepatocellular carcinoma in mainland China. This trial aims to assess the pharmacokinetic profiles, efficacy, safety, and immunogenicity of HLX13 compared to its reference product, YERVOY. The study’s successful progression could enhance the company’s market position in the oncology biosimilar sector, potentially impacting stakeholders positively by expanding treatment options for various cancers.
Shanghai Henlius Biotech, Inc. has been included in the MSCI Global Small Cap Indexes, effective after the market close on May 30, 2025. This inclusion is significant as the MSCI Indexes are widely referenced by international investment institutions, potentially enhancing the company’s visibility and attractiveness to investors.
Shanghai Henlius Biotech, Inc. successfully held its Annual General Meeting (AGM) on May 8, 2025, where all proposed resolutions were passed with significant shareholder support. The resolutions included the approval of the company’s annual report, board work report, board of supervisors’ work report, and final accounts report for the year 2024, reflecting strong operational performance and governance.
Shanghai Henlius Biotech, Inc. has entered into a license agreement with Sandoz AG to commercialize its HLX13, a recombinant anti-CTLA-4 fully human monoclonal antibody injection, across the United States, 42 European countries, Japan, Australia, and Canada. This agreement includes significant financial terms, such as an upfront payment of $31 million, potential milestone payments totaling $160 million, and sales milestone payments up to $110 million, along with double-digit tiered royalties. The deal is expected to enhance Henlius’s market presence in the oncology sector, leveraging Sandoz’s commercialization capabilities in major global markets.
Shanghai Henlius Biotech, Inc. has received approval in Germany for an international multi-center phase 3 clinical trial of its HLX22 monoclonal antibody in combination with other therapies for the treatment of HER2-positive gastroesophageal junction and gastric cancer. This development marks a significant step in the company’s efforts to expand its clinical trials across multiple regions, potentially enhancing its market positioning and offering new treatment options for patients with these types of cancer.
Shanghai Henlius Biotech, Inc. has entered into a license agreement with Alvogen Korea to commercialize its serplulimab injection, HANSIZHUANG, in South Korea. This agreement grants Alvogen Korea exclusive rights to market the drug for various cancers, potentially enhancing Henlius’s market presence in Asia and providing significant financial milestones and royalties.
Shanghai Henlius Biotech, Inc. announced that the first patient has been dosed in a phase 2 clinical study of their innovative product HLX22, in combination with trastuzumab deruxtecan, for treating HER2-low, HR-positive locally advanced or metastatic breast cancer in mainland China. This study aims to evaluate the efficacy and safety of this combination therapy, which has shown promising preclinical results, potentially offering a new therapeutic strategy for patients with HER2-expressing tumors.
Shanghai Henlius Biotech, Inc. has announced its upcoming Annual General Meeting (AGM) scheduled for May 8, 2025, where shareholders will consider and approve various resolutions. These include the company’s annual report, financial accounts, profit distribution, and budget proposals for the years 2024 and 2025. Additionally, the meeting will address the re-appointment of auditors and remuneration packages. A special resolution will be considered to grant the board a mandate to issue shares, which could impact the company’s capital structure and market operations.
Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a phase 1b/2 clinical trial of HLX43, an antibody-drug conjugate targeting PD-L1, in combination with HANSIZHUANG for treating advanced/metastatic solid tumors in mainland China. This trial aims to evaluate the safety and efficacy of the combination therapy, which could offer more effective and safer clinical solutions, as no similar combination therapy has been approved globally.
Shanghai Henlius Biotech, Inc. announced that its phase 3 clinical study of HLX04-O, a recombinant anti-VEGF humanized monoclonal antibody injection for treating wet age-related macular degeneration (wAMD), has successfully met its primary endpoint. This development positions the company to potentially enter a market in mainland China where no bevacizumab products have yet been approved for wAMD, indicating a significant opportunity for growth and impact on stakeholders.
Shanghai Henlius Biotech, Inc. announced that its marketing authorization application for HLX11, a pertuzumab biosimilar, has been validated by the European Medicines Agency. This development marks a significant step in the company’s global expansion strategy, as HLX11 is intended for various breast cancer treatments. The validation by the EMA could enhance the company’s market positioning in the oncology sector, potentially impacting stakeholders positively by opening up new market opportunities outside of China.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in Japan for its international multi-center phase 3 clinical study of HLX22, a recombinant humanized anti-HER2 monoclonal antibody injection, in combination with Trastuzumab and chemotherapy for treating HER2-positive, locally advanced or metastatic gastroesophageal junction and gastric cancer. This development marks a significant step in the company’s research efforts, potentially enhancing its position in the oncology market and offering new treatment options for patients with these aggressive cancers.
Shanghai Henlius Biotech, Inc. announced the approval of a phase 2 clinical trial for HLX79 injection in combination with HANLIKANG for treating active glomerulonephritis. This development marks a significant step in the company’s efforts to enhance treatment options for autoimmune diseases. The combination therapy is expected to improve B lymphocyte depletion, offering potential benefits to patients with glomerulonephritis. As no similar combination has been approved globally, this positions Shanghai Henlius Biotech as a pioneer in this therapeutic area, potentially impacting its market positioning and offering new hope for stakeholders.
Shanghai Henlius Biotech, Inc. has renewed two key procurement agreements with Fosun High Tech for one year, extending their collaboration until the end of 2025. These agreements, covering general procurement and IT-related services, are crucial for the company’s operational efficiency and compliance with listing rules, highlighting the strategic importance of their partnership with a major shareholder.
Shanghai Henlius Biotech, Inc. has announced its intention to implement the H Share Full Circulation, allowing domestic unlisted shares to be converted into H shares and traded on the Hong Kong Stock Exchange. This move, pending regulatory approvals, aims to enhance the liquidity and marketability of the company’s shares, potentially impacting its market positioning and offering new opportunities for shareholders and investors.
Shanghai Henlius Biotech, Inc. reported a 6.1% increase in total revenue for 2024, reaching approximately RMB5,724.4 million, driven by drug sales and R&D services. The company’s profit rose to RMB820.5 million, attributed to increased sales of core products. Key drug approvals in the US, Canada, and other countries for treatments like HANQUYOU and HANSIZHUANG enhance the company’s market position and offer potential growth opportunities.
Shanghai Henlius Biotech, Inc. has announced a series of organizational changes, including the re-designation of Mr. Wenjie Zhang from an executive to a non-executive director, effective March 24, 2025. Additionally, Dr. Jun Zhu has been appointed as an authorized representative, and the company is proposing amendments to its Articles of Association to align with updated laws and regulations, subject to shareholder approval at the upcoming annual general meeting.
Shanghai Henlius Biotech, Inc. announced the composition of its board of directors and their respective roles within the company. This announcement outlines the leadership structure, which is crucial for stakeholders to understand the governance and strategic direction of the company. The board includes a mix of executive, non-executive, and independent non-executive directors, indicating a diverse leadership team poised to guide the company in its industry pursuits.
Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius USA Inc., has received Orphan-drug Designation from the U.S. FDA for HLX22, a recombinant humanized anti-HER2 monoclonal antibody, for the treatment of gastric cancer. This designation is a significant milestone for the company, potentially enhancing its market position in the oncology sector. The global sales of HER2-targeting monoclonal antibody products are substantial, indicating a promising market for HLX22. The company is advancing clinical trials for HLX22 in multiple countries, which could lead to expanded treatment options for patients with HER2-positive cancers.